[2] Along with its headquarters in Seoul, South Korea, the company has subsidiaries in the U.S., Canada, Germany, Italy, Mexico, Brazil, and the Middle East.

In September 2010, Seegene undertook a $16.6 million initial public offering to list on KOSDAQ, a trading board of Korea Exchange (KRX).

[3] Seegene’s primary product focus is multiplex diagnostic assays, which allow for the detection and quantification of multiple pathogens from a single sample.

[6] Seegene moved quickly in January 2020 to begin developing a diagnostic for what would later be dubbed COVID-19, leveraging its proprietary artificial intelligence technology and SARS-CoV-2 genetic details that had been released online.

In February 2021, Seegene was disciplined by Korea’s Securities and Futures Commission for accounting errors and deficiencies taking place in the company’s early years of operation.